Limb-sparing treatment for canine osteosarcoma to be explored in new studyNovember 14, 2023The new research is set to evaluate the effectiveness of a novel drug combination tailored to giant-breed dogs diagnosed with osteosarcoma.
SPONSORED CONTENTHow can you help new pet owners keep their new dogs protected?See why new dog owners and their pets can benefit from simple triple protection in one monthly chew. + See the Difference
Individualized care central to trial canine oral cancer treatment methodSeptember 10, 2021Dogs diagnosed with a rapidly metastatic form of oral cancer may soon have access to a novel alternative treatment, thanks to a newly launched clinical trial.
ELIAS presents preliminary canine osteosarcoma results at ACVIMAugust 3, 2018During the 2018 American College of Veterinary Internal Medicine Forum in June, ELIAS Animal Health, a clinical stage development company advancing novel treatments for companion animal cancer, shared preliminary canine osteosarcoma results for its cancer immunotherapy. According to study results presented by Brian Flesner, DVM, DACVIM (Oncology), University of Missouri, the company's new ELIAS autologous cancer vaccine, featuring a patented vaccine and T cell infusion combination approach, demonstrated "impressive survival times and minimal side effects." This cancer immunotherapeutic is being distributed as an experimental product under 9 CFR 103.3 to veterinarians treating dogs diagnosed with cancer. Efficacy and safety have not been established. One in four dogs will be impacted by cancer in their lifetimes, and cancer is the No. 1 cause of death in dogs older than 2. "There has been growing frustration in the veterinary profession with current treatment options, including chemotherapy and radiation, which have only modestly improved outcomes over the past 20 years," said Noe Reyes, DVM, medical director, ELIAS Animal Health. "We are very encouraged by the positive treatment outcomes reported by Dr. Flesner at ACVIM and look forward to starting our pivotal osteosarcoma trial evaluating this T cell-based immunotherapy in a broader population," …
